Wave Life Sciences

WVE

Market cap $1.3B

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that it will host a virtual Research Day on Wednesday, October 29, 2025 at 10:00 a.m. ET. In addition, members of Wave's management team are scheduled to participate in several upcoming investor conferences. Details are as follows:

Wave Life Sciences Ltd. (NASDAQ:WVE ) Positive RestorAATion-2 Clinical Data Update Transcript Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Christopher Wright - Chief Medical Officer Erik Ingelsson - Chief Scientific Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Joon Lee - Truist Securities, Inc., Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Benjamin Paluch - Citi Jiale Song - Jefferies LLC, Research Division Yun Zhong - Wedbush Securities Inc., Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Madison Wynne El-Saadi - B.

Wave Life Sciences Ltd. WVE stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)

Wave (WVE) Q2 Revenue Drops 56%

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Erik Ingelsson - Chief Scientific Officer Kate Rausch - Head of Investor Relations Kyle B.

Wave Life Sciences (WVE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.25 per share a year ago.

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg)